Full Breakdown
ByHeart Infant Botulism Outbreak Concludes with 48 Affected Infants
2/27/2026, 1:54:31 AM
Overview of the Outbreak
The U.S. Centers for Disease Control and Prevention (CDC) has declared the multistate outbreak of infant botulism linked to ByHeart powdered infant formula officially over, with no new cases reported since mid-December 2025. A total of 48 infants were affected, all of whom required hospitalization, but no fatalities occurred. The outbreak, which began in 2023, was characterized by a concerning rise in cases detected primarily after August 2025, prompting an investigation by health officials.
Timeline of Events
- August 2025: California's Infant Botulism Treatment and Prevention Program notices an increase in infant botulism cases associated with ByHeart formula.
- November 2025: ByHeart recalls two specific lots of formula, later expanding the recall to all products.
- December 10, 2025: CDC reports no new cases since this date.
- February 26, 2026: CDC officially declares the outbreak over.
Investigation and Findings
The investigation into the outbreak revealed that 28 cases were confirmed as infant botulism, while 20 were classified as probable. The CDC and the Food and Drug Administration (FDA) are continuing to investigate the root cause of the contamination. Initial findings linked the outbreak to whole-milk powder sourced from a supplier, with 17 different strains of the bacteria Clostridium botulinum identified in samples from patients and products. Despite these findings, the FDA has not yet determined a definitive source of contamination.
Health Implications
Infant botulism occurs when infants ingest spores of the bacteria, which can grow in their immature digestive systems and produce a toxin that affects the nervous system. Symptoms include constipation, poor feeding, and in severe cases, breathing difficulties. The only treatment available is an intravenous medication known as BabyBIG, which is produced from the blood plasma of adults immunized against botulism. California's specialized program is the sole global supplier of this treatment.
Market Impact
ByHeart, which accounted for approximately 1% of the U.S. infant formula market, previously sold around 200,000 cans of formula monthly. Parents chose this formula, priced at about $42 per can, due to its advertised health benefits. The unprecedented scale of this outbreak has raised concerns among food safety experts, although it does not currently pose a risk of infant formula shortages.
Official Statements & Responses
The CDC stated, "This outbreak is over, but activities to determine the root cause of C. botulinum in ByHeart powdered infant formula continue." The FDA emphasized the complexity of identifying the source of Clostridium botulinum contamination and noted that further analysis and research are necessary.
Criticism & Opposition
Some parents expressed frustration over the lack of clarity regarding how the contamination occurred and the potential risks associated with the formula they chose for their infants. The unprecedented nature of this outbreak has led to calls for increased scrutiny and regulation of infant formula production.
What's Next
As the investigation continues, the FDA is transitioning from immediate response activities to post-incident actions, which may include enhanced surveillance and compliance measures to ensure the safety of powdered infant formula. Further updates on the investigation will be provided as new information becomes available.
